This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
12 Feb 2011

Crucell Resumes Selling Vaccine

Crucell NV can resume selling its top vaccine Quinvaxem to United Nations agencies, after the WHO said Thursday that the company has resolved manufacturing problems at its plant in South Korea.

Dutch biotech company Crucell NV can sell new lots of  vaccine Quinvaxem to United Nations agencies, after investigations by the World Health Organization showed the manufacturing problems at Crucell’s plant in South Korea were resolved. Crucell suspended production due to sterility issues at the plant and stopped shipments of two children’s vaccines, including Quinvaxem.

The manufacturing problems resulted in a loss for the company in 2010 and put on hold Johnson & Johnson’s $2.4 billion bid to takeover the company. J&J’s bid expires February 16th; the company currently holds about 18% of Crucell shares.


Related News